PYXS pyxisoncology.com: Projected Price to Earnings

Pyxis Oncology, Inc. (PYXS) focuses on developing therapies that enable the body's own immune system to combat tumors. Strict regulatory requirements and high development costs create a high barrier to entry in the sector. Historical price action based on the P/E ratio is recorded at 0.00. The company expands its product portfolio through strategic partnerships and the targeted acquisition of third-party patents.

Pyxis Oncology, Inc. - PYXS Future Price to Earnings Multiple (period 07/04/2022 - 11/15/2026)

Metric breakdowns and analytics for pyxisoncology.com (PYXS)

- stock quotes and analyst forecast:

Stock Price Pyxis Oncology|PYXS - Analyst Target Range

- company stock capitalization data:

Market Valuation Pyxis Oncology Inc.|PYXS - Total Enterprise Value

- issuer book value statistics:

Accounting Value per Share Pyxis Oncology|PYXS - Accounting Value of Company|Market Capitalization to Book Value Ratio pyxisoncology.com|PYXS - Company Total Asset Base

- debt level and financial liquidity data:

- financial results and valuation multiples details:

PYXS - Company Net Income|Future Profit Pyxis Oncology, Inc.|PYXS - Market Cap to Net Income Ratio|Projected Price to Earnings Pyxis Oncology, Inc.|PYXS - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Pyxis Oncology|PYXS - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Pyxis Oncology|PYXS - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months pyxisoncology.com|PYXS - Earnings per share increase in current year|Earnings growth forecast for next year Pyxis Oncology, Inc.

- sales volume and revenue information:

PYXS - Revenue and Sales Volume|Company Projected Revenue pyxisoncology.com|PYXS - Price-to-Sales Ratio|Forward Price-to-Revenue Multiple Pyxis Oncology Inc.|PYXS - Trailing Twelve Months Revenue Growth

Fundamental company analysis:Pyxis Oncology Inc. PYXS

Signature product of Pyxis Oncology, Inc.

Pyxis Oncology, Inc. (PYXS) develops innovative therapies for aggressive oncological diseases. The forward P/E compares current market capitalization with expected earnings and US industry standards. By analyzing the company's projected P/E, an investor assesses market optimism regarding the success of clinical trials. A rise in this metric above the historical average signals inflated expectations, which creates the risk of overpayment in the absence of confirmed drug efficacy.

Analysis of competing companies